Phase I, Open-label, Dose-Ranging Study to Evaluate the Safety, Tolerability, and Immunogenicity of GLS-5700 Administered ID Followed by EP in Dengue Virus-Naïve Adults

Trial Profile

Phase I, Open-label, Dose-Ranging Study to Evaluate the Safety, Tolerability, and Immunogenicity of GLS-5700 Administered ID Followed by EP in Dengue Virus-Naïve Adults

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 04 Oct 2017

At a glance

  • Drugs GLS 5700 (Primary)
  • Indications Zika virus infection
  • Focus Adverse reactions; First in man
  • Sponsors GeneOne Life Science
  • Most Recent Events

    • 04 Oct 2017 Interim analysis results at 14 weeks, published in the New England Journal of Medicine.
    • 07 Jun 2017 Results published in the Inovio Pharmaceuticals media release.
    • 07 Mar 2017 Planned primary completion date changed from 1 Nov 2016 to 1 Nov 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top